LIXTE BIOTECHNOLOGY HOLDINGS, INC. 8-K

What Happened
Lixte Biotechnology Holdings, Inc. (LIXT) filed an 8‑K reporting that the Board appointed Stuart D. Porter as a director effective May 29, 2026. Mr. Porter, age 60, will serve until the Company’s 2026 Annual Meeting of Stockholders. The company furnished a press release under Regulation FD as Exhibit 99.1.

Key Details

• Appointment date: May 29, 2026; term expires at the 2026 Annual Meeting.
• New director: Stuart D. Porter, ~29+ years of senior investment experience.
• Current roles: Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital; member of Denham’s Investment and Valuation Committees.
• Background: Prior roles include founding partner at Sowood Capital Management, VP/Portfolio Manager at Harvard Management Company, and positions at J. Aron (Goldman Sachs), Bacon Investments, Cargill; BA from University of Michigan, MBA from University of Chicago Booth.
• Corporate governance notes: No arrangements or understandings relating to his selection; no transactions with Mr. Porter reportable under Item 404(a) of Regulation S‑K.

Why It Matters
A new independent director with extensive investment and commodity/energy experience has been added to Lixte’s Board, which can influence oversight and strategic guidance. The filing is routine disclosure of a board change and includes a press release; there are no related‑party transaction issues disclosed. Investors should note the date of appointment and that the term expires at the upcoming 2026 annual meeting.